Company Analysis
Sign in

Vir Biotechnology, Inc. (VIR)

Nasdaq: VIR · Biological Products, (No Diagnostic Substances) · San Francisco, CA · filing with the SEC since 2018
Full chart Alerts Compare
Grade5.2
◀ Past 7.1● Present 4.3▶ Future 4.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

39 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Vir Biotechnology, Inc.’s names, not what it holds today.

Patents granted
39
39 utility, 1976 to Dec 31, 2025
Granted in 2025
6
Against 6 in 2024 and 4 in 2023
Applications published
106
11 of them in 2025
Names they are printed under
5
a subsidiary, its own name
By yearGrantedApplications published
'14'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals25
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
HUMABS BIOMED SA a subsidiary
named as the applicant on its applications, in CH. 2 more under the same name are not counted (printed in CN, printed in SZ)
0 granted
54 published
HUMABS BIOMED SA a subsidiary
CH, as the owner printed on each patent
38 granted
3 published
Vir Biotechnology, Inc. its own name
named as the applicant on its applications, in US
0 granted
32 published
Agenovir Corporation a subsidiary
named as the applicant on its applications, in US
0 granted
17 published
Agenovir Corporation a subsidiary
US, as the owner printed on each patent
1 granted
0 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 9, 202512,492,240Neutralizing anti-influenza A antibodies and uses thereofPharmaceuticalsHUMABS BIOMED SA
Sep 2, 202512,404,318Combination HBV therapyPharmaceuticalsHUMABS BIOMED SA
Jun 10, 202512,325,740Neutralizing anti-influenza B antibodies and uses thereofPharmaceuticalsHUMABS BIOMED SA
May 27, 202512,312,397Anti-O2 antibodies and uses thereofPharmaceuticalsHUMABS BIOMED SA
May 20, 202512,304,946Antibodies that neutralize hepatitis B virus and uses thereofPharmaceuticalsHUMABS BIOMED SA
May 13, 202512,297,258Antibodies against Campylobacter speciesPharmaceuticalsHUMABS BIOMED SA
Jul 16, 202412,037,381Antibodies that potently neutralize hepatitis B virus and uses thereofPharmaceuticalsHUMABS BIOMED SA
Jun 25, 202412,018,068Anti-O1 antibodies and uses thereofPharmaceuticalsHUMABS BIOMED SA
Apr 30, 202411,970,527Antibody directed against S. aureus clumping factor A (ClfA)PharmaceuticalsHUMABS BIOMED SA
Mar 19, 202411,932,682Neutralizing anti-influenza A antibodies and uses thereofPharmaceuticalsHUMABS BIOMED SA
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 4, 20252025/0368723ANTI-O2 ANTIBODIES AND USES THEREOFPharmaceuticalsHUMABS BIOMED SA
Nov 20, 20252025/0353900ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOFPharmaceuticalsHUMABS BIOMED SA
Oct 16, 20252025/0320497COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASESPharmaceuticalsVir Biotechnology, Inc.
Oct 2, 20252025/0302951COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASESPharmaceuticalsVir Biotechnology, Inc.
Sep 25, 20252025/0296986ENGINEERED POLYPEPTIDESBiotechnologyVir Biotechnology, Inc.
Aug 21, 20252025/0263470NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOFPharmaceuticalsHUMABS BIOMED SA
Aug 21, 20252025/0263467ANTIBODY THERAPIES FOR SARS-COV-2 INFECTIONPharmaceuticalsVir Biotechnology, Inc.
Aug 21, 20252025/0263466ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAMEBiotechnologyVir Biotechnology, Inc.
Jun 5, 20252025/0179424ENGINEERED MICROORGANISMS AND METHODS OF MAKING AND USING SAMEBiotechnologyVir Biotechnology, Inc.
May 1, 20252025/0136949METHODS FOR PRODUCING CMV VECTORSBiotechnologyVir Biotechnology, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 23 · Biotechnology 6 · Computer technology 1 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VIR · research, not advice